摘要
嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)的出现使得多发性骨髓瘤(multiple myeloma,MM)患者的治疗进入了一个新的阶段,但大多数患者都难逃原发耐药或疾病复发的不良结局。G蛋白偶联受体C类5组成员D(G protein-coupled receptor class C group 5 member D,GPRC5D)是目前MM患者的一个有前景的治疗靶点,与GPRC5D CAR-T相关的Ⅰ期临床研究也都显示出较高的反应率和疗效。文章将对现有的靶向GPRC5D CAR-T细胞最新研究进行综述,旨在通过总结讨论目前不同GPRC5D CAR-T细胞治疗复发难治性MM的研究现状,对今后的临床治疗提供更多参考。
The emergence of chimeric antigen receptor T cells(CAR-T)has brought the treatment of multiple myeloma(MM)to a new stage,but most patients cannot escape the adverse outcome of primary drug resistance or disease recurrence.G protein-coupled receptor class C group 5 member D(GPRC5D)is currently a promising therapeutic target for MM patients,and the phase I clinical studies of GPRC5D CAR-T have also shown high response rates and efficacy.This article reviews the latest research on GPRC5D CAR-T cells,aiming to provide more references for future clinical treatment by summarizing and discussing the current research status of different GPRC5D CAR-T cells in the treatment of relapsed and refractory multiple myeloma.
作者
张明月
李娜
赵江珊
王雪莹
石琳
ZHANG Mingyue;LI Na;ZHAO Jiangshan;WANG Xueying;SHI Lin(The Second Clinical Medical College of Henan University of Chinese Medicine,Zhengzhou,450002,China;Department of Hematology Oncology,Pingdingshan City First People's Hospital;Department of Hematology,Henan Provincial Hospital of Traditional Chinese Medicine)
出处
《临床血液学杂志》
2025年第7期572-576,共5页
Journal of Clinical Hematology
基金
河南省中医药科学研究专项课题(No:2021ZY1051)。
作者简介
通信作者:石琳,E-mail:slin7085@163.com。
